文献速递胸部肿瘤

阿来替尼在ALK阳性非小细胞肺癌中的I/II期研究AF-001JP的三年随访

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.
PubMed 文献 · J Clin Oncol · 2017-03-15

AF-001JP II期部分纳入46例未接受过ALK抑制剂的ALK阳性非小细胞肺癌患者,口服阿来替尼300 mg每日两次。3年随访时中位无进展生存期未达到,3年无进展生存率为62%(95% CI 45-75),3年总生存率为78%(13例事件)。结论认为阿来替尼在这3年随访中有效且长期给药安全性良好。

要点

  • 46例II期患者中18例(39%)确认疾病进展,中位无进展生存期未达到,3年无进展生存率为62%(95% CI 45-75)。
  • 14例基线脑转移患者中6例仍在研究且无中枢神经系统和全身进展。
  • 3年总生存率为78%(13例事件);最常见治疗相关不良事件(所有级别)为血胆红素升高(36.2%)。

核心结论

  • 阿来替尼在未接受过ALK抑制剂的ALK阳性非小细胞肺癌患者中,经3年随访显示有效且长期给药安全性良好。

研究设计与样本

  • AF-001JP的II期部分长期随访,纳入46例未接受过ALK抑制剂、既往化疗后进展的ALK阳性非小细胞肺癌患者,口服阿来替尼300 mg每日两次。
  • 更新数据截止日期为2015年9月10日,首例患者入组2011年8月30日,末例患者入组2012年4月18日。

主要发现

  • 46例II期患者中25例仍在接受阿来替尼治疗,18例(39%)确认疾病进展;中位无进展生存期未达到,3年无进展生存率为62%(95% CI 45-75)。
  • 14例基线脑转移患者中6例仍在研究且无中枢神经系统和全身进展。
  • 肿瘤缩小与无进展生存期无相关性。
  • 3年总生存率为78%(13例事件)。
  • 最常见治疗相关不良事件(所有级别)为血胆红素升高(36.2%);多数癌症症状早期缓解,对症药物在阿来替尼治疗期间显著减少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Alectinib is an anaplastic lymphoma kinase (ALK) -specific kinase inhibitor that seems to be effective against non-small-cell lung cancer (NSCLC) with a variety of ALK mutations. The primary analysis of AF-001JP reported a promising overall response rate. To assess progression-free survival (PFS) and overall survival (OS), patients from the phase II part of AF-001JP were followed up for approximately 3 years. Patients and Methods Oral alectinib 300 mg was administered twice per day to patients with ALK inhibitor-naïve, ALK-positive NSCLC who had progressed after one or more regimens of previous chemotherapy. In this long-term follow-up, efficacy (PFS, OS), correlation between tumor shrinkage and PFS, safety of alectinib, and relief of cancer symptoms were evaluated. Results At the updated data cutoff (September 10, 2015; first patient in August 30, 2011, last patient in April 18, 2012), 25 of 46 phase II patients were still receiving alectinib. Disease progression was confirmed in 18 patients (39%); median PFS was not reached (3-year PFS rate, 62%; 95% CI, 45 to 75). Fourteen patients had brain metastases at baseline; of these, 6 remained in the study without CNS and systemic progression. Tumor shrinkage and PFS showed no correlation. The 3-year OS rate was 78% (13 events). The most common treatment-related adverse event (all grades) was increased blood bilirubin (36.2%). Most cancer symptoms were relieved early, and medication for symptoms was dramatically decreased during alectinib therapy. Conclusion Alectinib was effective in this 3-year follow-up with a favorable safety profile over a long administration period in ALK-positive NSCLC without previous ALK inhibitor treatment.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tamura T, Kiura K, Seto T, et al. Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP. J Clin Oncol. 2017. PMID: 28296581. doi:10.1200/JCO.2016.70.5749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。